1 day ago
9
Health|From No Hope to a Potential Cure for a Deadly Blood Cancer
https://www.nytimes.com/2025/06/03/health/multiple-myeloma-car-t-immunotherapy.html
You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.
Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.
June 3, 2025, 10:45 a.m. ET
A group of 97 patients had longstanding multiple myeloma, a common blood cancer that doctors consider incurable, and faced a certain, and extremely painful, death within about a year.
They had gone through a series of treatments, each of which controlled their disease for a while. But then it came back, as it always does. They reached the stage where they had no more options and were facing hospice.
They all got immunotherapy, in a study that was a last-ditch effort.
A third responded so well that they got what seems to be an astonishing reprieve. The immunotherapy developed by Legend Biotech, a company founded in China, seems to have made their cancer disappear. And after five years, it still has not returned in those patients — a result never before seen in this disease.
These results, in patients whose situation had seemed hopeless, has led some battle-worn American oncologists to dare to say the words “potential cure.”
“In my 30 years in oncology, we haven’t talked about curing myeloma,” said Dr. Norman Sharpless, a former director of the National Cancer Institute who is now a professor of cancer policy and innovation at the University of North Carolina School of Medicine. “This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.”
The new study, reported Tuesday at the annual conference of the American Society of Clinical Oncology and published in The Journal of Clinical Oncology, was funded by Johnson & Johnson, which bought Legend Biotech.
